AI Article Synopsis
Article Abstract
Background: The prognosis of high-grade glioma in children is poor.
Purpose: Interferon-gamma may increase the immune surveillance of glioma cells. Earlier clinical evidence had shown that low dose cyclophosphamide (CPM) increased immune response.
Methods: After induction treatment with simultaneous radiation and chemotherapy, patients were treated with individually increasing interferon-gamma (IFN-gamma) doses starting from 25 microg/m2/d s.c. increasing up to a maximum of 175 microg/m2/d within 7 weeks. Cyclophosphamide was given at 300 mg/m2 i.v. every 21 days. Forty pediatric glioma patients were enrolled (median age: 8.5 year, male: n = 22). Tumor locations included cerebral cortex (n = 8), basal ganglia (n = 4), brainstem (n = 24), cerebellum (n = 3), spinal cord (n = 1). Histologies were GBM (n = 14), AA (n = 14), LGG (n = 2, diffuse intrinsic pontine glioma). There was grade IV toxicity for thrombocytopenia (10%) and leucopenia (2.5%), grade III toxicity for central nervous (2.5%) and hepatic (5%) side effects, no toxic death. The observation time of the six surviving patients was: 1.2, 1.9, 4.2, 4.4, 4.6 and 4.7 years respectively. The median overall survival (1 year) was not significantly different from a historical control group (0.8 years). The survival of pontine gliomas appeared even inferior when compared to the previous protocol (n.s.).
Conclusion: Maintenance treatment with IFN-gamma and low dose CPM has no sufficient beneficial effect for the treatment of high-grade glioma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11060-006-9147-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Coati optimization algorithm for brain tumor identification based on MRI with utilizing phase-aware composite deep neural network.
Electromagn Biol Med
January 2025
Department of Computer Applications, Kalasalingam Academy of Research and Education - Deemed to be University, Krishnankoil, India.
Brain tumors can cause difficulties in normal brain function and are capable of developing in various regions of the brain. Malignant tumours can develop quickly, pass through neighboring tissues, and extend to further brain regions or the central nervous system. In contrast, healthy tumors typically develop slowly and do not invade surrounding tissues.
View Article and Find Full Text PDFAberrant FGF signaling promotes granule neuron precursor expansion in SHH subgroup infantile medulloblastoma.
Elife
January 2025
Department of Neurology, Weill Institute for Neuroscience, University of California San Francisco, San Francisco, United States.
Mutations in Sonic Hedgehog (SHH) signaling pathway genes, for example, (SUFU), drive granule neuron precursors (GNP) to form medulloblastomas (MB). However, how different molecular lesions in the Shh pathway drive transformation is frequently unclear, and mutations in the cerebellum seem distinct. In this study, we show that fibroblast growth factor 5 (FGF5) signaling is integral for many infantile MB cases and that expression is uniquely upregulated in infantile MB tumors.
View Article and Find Full Text PDFIdiopathic Optic Nerve Glioma: A Case Report.
Cureus
December 2024
Department of Ophthalmology, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, IND.
Optic nerve gliomas are tumors that develop along the optic nerve pathway, most often classified as pilocytic astrocytomas. These growths are typically benign, especially in young children between the ages of one and six years, while the rarer malignant types are generally more aggressive and tend to appear in adults. Characteristically slow-growing, optic nerve gliomas are commonly located in the pre-chiasmal part of the optic nerve but can extend to post-chiasmal regions and into the brain if left untreated.
View Article and Find Full Text PDFTingling, Numbness, and Underlying Malignancy: A Case Report of Glioblastoma Multiforme.
Cureus
December 2024
General Medicine, Dartford and Gravesham NHS Trust, Dartford, GBR.
Glioblastoma multiforme (GBM) is a World Health Organisation (WHO) grade IV glioma originating from astrocytes. It is the most common malignant primary tumour of the brain and central nervous system (CNS) and is associated with fast progression and violent local spread, with a median overall survival of approximately 15 months after diagnosis. Due to its late and varied presentation, it is often diagnosed only after it has grown considerably.
View Article and Find Full Text PDFAssociation Between Polymorphisms in DNA Repair Genes and Glioma Susceptibility: A Meta-Analysis of Four Single Nucleotide Polymorphisms (rs3212986, rs13181, rs25487, and rs861539).
Cureus
December 2024
Department of Neurosurgery, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, GRC.
Cases with central nervous system tumors represent a small amount of all tumors, and the diagnosis of high-grade gliomas (HGGs) is mostly difficult as they frequently show intratumoral morphological heterogeneity. Genetic factors, such as single nucleotide polymorphisms (SNPs), have an important role in modifying glioma susceptibility. We conducted a comprehensive meta-analysis to investigate the ERCC1 (rs3212986), ERCC2 (rs13181), XRCC1 (rs25487), and XRCC3 (rs861539) genes to see if they are any risk factors for glioma susceptibility.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!